Showing posts with label disease diabetes. Show all posts
Showing posts with label disease diabetes. Show all posts

Tuesday, July 31, 2007

Experimental therapy reverses diabetes in mice

An experimental new combination therapy has reversed type I diabetes in mice, thanks in part to a novel focus on combating insulin resistance in this form of the disease, US researchers said Monday.

Insulin resistance has long been a recognised feature of type II or late-onset diabetes, but has only recently been identified as a component of juvenile or type I diabetes.

With this study, investigators have shown for the first time that treating inflammation related to insulin resistance as well as the autoimmune component of the disease can successfully reverse the disease, if it is caught early enough.

"We believe this is the first study to show inflammation in insulin sensitive tissues plays an important role in this disease," said Terry Strom, a professor of medicine at Harvard Medical School and co-author of the paper.

Type I diabetes is an autoimmune disorder in which the body's own immune system attacks the pancreatic cells that produce the hormone insulin which regulates blood sugar.

The result is that the patient cannot produce enough insulin of their own, and has to supplement with synthetic versions of the hormone, typically by injection.

The condition raises an individual's risk for a host of complications, including heart disease, blindness and nerve damage.

In this experiment, investigators treated newly diabetic mice with a cocktail of three substances that prevented the body's own T-cells from destroying the pancreatic cells that produce insulin and also eliminated the inflammation that impaired the ability of tissues in the muscles, fat and liver to metabolise insulin properly.

The mice were treated for a period of 14 or 28 days, and within five to seven weeks, 95 per cent of them had normal blood sugar levels and were able to control their blood sugar for 300 days.

In contrast, the untreated diabetic mice became hypoglycemic and most died within seven weeks even with insulin treatment.

The results suggest any therapy that hopes to arrest the development of diabetes in humans must not only tackle the T-cell disorder, but it must also restore insulin responsiveness in tissues affected by an inflammatory disorder.

Otherwise, the body's remaining insulin-producing beta cells have to work twice as hard to regulate blood sugar levels.

"The remnants of the beta cells have to work overtime to try and maintain blood sugar levels," explained Strom.

Strom said that clinical trials of the treatment in humans would begin within 12 months.

The study appears in the Proceedings of the National Academy of Sciences.

Source:www.channelnewsasia.com

Tuesday, July 17, 2007

New Survey Reveals Public's Willingness to Self-Manage Chronic Disease - Patient Reality Shows Different Story

As a new Survey Shows the Public's Willingness to Embrace Self- Management of Chronic Disease, Roche Diagnostics is Running an Awareness Campaign to Encourage Diagnosed Patients to Take Advantage of the Information, Support and Technologies That are Available to Them
A new survey conducted on behalf of Roche Diagnostics has found that eight out of ten adults would be willing to embrace self-management if they were diagnosed with a chronic condition, such as diabetes or cardiovascular disease(i). Yet of those who are currently diagosed with diabetes for example, two out of five adults have poor blood glucose management putting them at risk of complications(ii).
Roche Diagnostics, a pioneer in monitoring solutions for people with chronic diseases, is driving a campaign for greater awareness of the information, support and technologies that are available to help patients in the self-management of their condition.
There are currently 17.5 million people in the UK who have a long-term health condition(iii). The cost of caring for the complications associated with these conditions is rising, and with diabetes alone it is around GBP1 billion every year(iv). Many complications are caused through poor self-management, which could be avoided if the patient was able to take advantage of the information, support and technologies that are available to them, such as education packs, monitoring systems, support groups and training courses(v).
Diabetes UK reports that only six per cent of their patient members undertook associated training available to them in support of their self-management in 2005.(vi)
With a burgeoning body of evidence pointing to the importance of blood glucose self-monitoring(vii), awareness of the available support is growing but could always be greater. One such study(viii) reviewed by Debbie Hicks, Nurse Consultant in Diabetes, showed a close association between self-monitoring of Type 2 diabetes with reducing serious complications (such as heart attack, stroke, blindness and amputation), and improved life expectancy.
The drive to raise awareness and access to information and education on the role of self-management is crucial considering that people with diabetes spend 8,757 hours a year self-managing their condition, compared to only three hours a year with a healthcare professional(ix).
Debbie Hicks said: "It is positive news that the concept of self-management is being embraced by the public, but it is clear that many people with diabetes are struggling as they fail to achieve good self-management. There is a wealth of support out there such as blood glucose monitoring systems and education packs, yet we need to raise greater awareness of their availability and encourage people to take advantage of them as appropriate. Speaking to a healthcare professional is one such way of sourcing this information."
With over 30 years' experience of diabetes care, Roche Diagnostics leads the way in providing innovative solutions and support tools for patients and their Healthcare Professionals to make living with diabetes easier. Through its range of Accu-Chek blood glucose monitoring devices, data management tools and insulin delivery systems, Roche is helping patients and HCPs to collect, analyse and act on information, and achieve greater control. To complete the circle of care, Roche also provides a 365 days a year Accu-Chek Customer Care Line for additional patient support(x). Roche Diagnostics is also committed to supporting patient access to blood glucose test strips, a crucial element in self-monitoring, and has produced in conjunction with the UK Association for Diabetes Specialist Nurses an information pack for people with diabetes(xi).
In conclusion Debbie Hicks said: "Successful patient self-management is vital and requires a potent mix of the correct treatment, usage of monitoring systems and good professional education and support. I welcome the fact that Roche is helping to raise awareness of this."
About Roche and the Roche Diagnostics Division
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of drugs for cancer and transplantation and a market leader in virology. In 2006 sales by the Pharmaceuticals Division totalled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai Roche's Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide.

source:www.itnews.it

Type 2 Diabetes Cuts Eight Years Off Life

A study published in the June 2007 Archives of Internal Medicine has calculated that a person with type 2 diabetes is more than twice as likely to develop heart disease as someone without diabetes.

Moreover, they're likely to get it about eight years sooner than people without diabetes and likely to die about eight years younger than non-diabetic people. The study used data from the Framingham Heart Study, which has examined more than 5,000 residents of Framingham, Massachusetts, every two years since 1948.

Specifically, the study revealed that fifty-year-old men with diabetes develop heart disease an average of 7.8 years sooner than non-diabetic men and die an average of 7.5 years earlier than non-diabetic men with heart disease.

Fifty-year-old women with diabetes develop heart disease 8.4 years sooner than non-diabetic women and die an average of 8.2 years earlier than non-diabetic women with heart disease.

People with diabetes live almost as many years after a diagnosis of heart disease as non-diabetic people do; the problem lies in the fact that they develop heart disease sooner, so they're younger when they run out of time.

Take heart, though, from the knowledge that even after diabetes has been diagnosed, heart disease can be prevented by a healthy lifestyle and proper medical care. There have been great advances in the prevention of heart disease, including the use of statins, since the Framingham study began, but the lifestyle-mediated explosion of type 2 diabetes bodes ill for the future.


source:www.diabeteshealth.com

Curry studied in Alzheimer's

The most active ingredient in Indian curry appears to help human immune cells remove substances implicated in Alzheimer's disease, researchers said Monday.

"We don't think it would be harmful to add curry to you diet," said Milan Fiala, researcher/professor at the University of California, Los Angeles/Greater Los Angeles Veterans Affairs Medical Center, "although it is too early in our experimentation to make recommendations about how much curry is needed to impact Alzheimer's disease."

Fiala and associates at UCLA began investigating curry because of epidemiological data that indicated that in populations in India where curry cuisine is common the incidence of Alzheimer's type dementia is low.

In a study published by the Proceeding of the National Academy of Sciences, the researchers determined that a compound called bisdemethoxycurcumin -- derived from the herb turmeric -- has the most actively. He said that the Indian curry he used is a mixture of different curcuminoids.

Fiala told United Press International that injection of bisdemethoxycurcumin boosted the ability of immune cells of some Alzheimer's patients to clear amyloid-beta, the destructive substance that causes buildup of plaques in the brains of Alzheimer's patients.

"We found, however," Fiala said, "that the addition of the curcuminoids doesn't work as well in some patients' cells as it does in others. That means there could be a genetic difference in some patients that would indicate a need for individualized treatment with such a compound in the future."

At present, there are no drugs or drug candidates based on the bisdemethoxycurcumin, he said, although laboratory tests using Alzheimer's patients' blood samples and the brains of deceased patients are continuing. In his studies, Fiala used a synthetic form of bisdemethoxycurcumin.

"The study provides more insight into the role of the immune system in Alzheimer's disease and points to a new treatment approach," he suggested. The laboratory researchers also identified genes involved in the process. These genes, MGAT III and Toll-like receptors, are also responsible for a number of other key functions in the immune system.

Turmeric, a yellowish herb, is often ground up and used in numerous curry dishes and other foods throughout India, Asia and the Middle East.

"These herbs have been used by indigenous peoples for treatment of neurological disorders such as epilepsy, so there could be something here," said Steven Pacia, director of neurology at Lenox Hill Hospital in New York.

"This is a fascinating study, especially in that it shows differences in how the immune system works in removing amyloid-beta from patients who are normal and who have Alzheimer's disease," he told UPI.

"Even more interesting is that it appears that the addition of this turmeric compound improves that removal of the amyloid-beta. It is the buildup of amyloid-beta in the brain that is the leading hypothesis for the cause of Alzheimer's disease," he said.

He said, however, that the studies were conducted using peripheral blood cells as opposed to cells from the brains of the patients and that it is possible that what is seen in the blood cells might not be happening in the brain cells.

"This is an interesting first step," he said.

Pacia said that intake of turmeric in various cuisines is unlikely to cause any medical problems, although there are always some people who have unexpected reactions to foods and spices.

He agreed that the scientific work being done in the test tube is still too early to consider any recommendations for increasing turmeric consumption.

Fiala suggested that if there is a family predisposition to dementia-type illnesses, these individuals might want to start developing a taste for Indian foods.

He said his research could lead to a prophylactic use of bisdemethoxycurcumin as well as a therapeutic drug.

"This study provides an unexpected benefit of how curry spices impact the immune system. This is not an area in which we were looking with these spices. It points us in a different direction that may help us unravel the way that Alzheimer's disease affects us," said Sam Gandy, chairman of the Alzheimer's Association's medical and scientific advisory council.

source:www.sciencedaily.com

XOMA Initiates Phase I U.S. Trial in Type 2 Diabetes for XOMA 052, Monoclonal Antibody With Therapeutic Potential in Multiple Inflammatory Diseases

XOMA Ltd. (Nasdaq:XOMA) today announced the initiation of Phase I clinical testing of product candidate XOMA 052, a potent monoclonal antibody targeting Interleukin-1 beta (IL-1 beta), in patients with Type 2 diabetes. IL-1, which plays a role in multiple inflammatory diseases, has been implicated in the pathogenesis of diabetes through the destruction of the pancreatic islet cells that produce insulin.

This U.S.-based study, designed to assess the safety and pharmacokinetics of XOMA 052, will enroll up to 72 subjects with Type 2 diabetes. XOMA plans to initiate a European-based Phase I clinical trial of XOMA 052 in Type 2 diabetes patients later in 2007. Safety data from both trials are expected to guide the development of XOMA 052 for additional indications, which may include rheumatoid arthritis, systemic juvenile idiopathic arthritis, and osteoarthritis.

"Anti-IL-1 beta therapy has the potential to significantly advance the approach to diabetes care by altering the disease state itself," said Jack Castello, chairman of the board, president and chief executive officer of XOMA. "XOMA 052, developed by XOMA using XOMA's antibody discovery and Human Engineering technologies and capabilities, offers the promise of improved therapy for major medical needs. We are pleased to be able to advance XOMA 052 to the clinic and look forward to evaluating options for its broader clinical development."

XOMA is working with Charles A. Dinarello, M.D., Marc Y. Donath, M.D., and Thomas Mandrup-Polsen, M.D., Ph.D., leading researchers of Type 2 diabetes and IL-1 beta. Dr. Donath commented, "I expect XOMA 052, when administered to patients with Type 2 diabetes, to provide an effective inhibition of the IL-1 beta cytokine released by insulin producing islet cells. This inhibition may substantially block the progression of the disease."

About Interleukin-1 and Inflammatory Disease

IL-1 is a pro-inflammatory cytokine secreted by a number of cell types including monocytes and macrophages. The IL-1 gene family includes IL-1 beta , which is released from cells as part of an inflammatory reaction. IL-1 beta produces a range of biological effects, mainly through the induction of other pro-inflammatory mediators such as corticotrophin, platelet factor-4, prostaglandin E2 (PGE2), IL-6, and IL-8. IL-1 beta induces both local and systemic inflammatory effects through the activation of the IL-1 receptor found on almost all cell types. IL-1 beta is implicated in the pathogenesis of many disease states involving localized and systemic inflammation. Targeting this pathway and reducing the effects of IL-1 beta may provide clinical benefit in rheumatoid arthritis, systemic juvenile idiopathic arthritis, osteoarthritis, and other inflammatory diseases.

About Interleukin-1 and Type 2 Diabetes

There is evidence that blocking the IL-1 pathway has improved the control of blood glucose. In the presence of high blood glucose, IL-1 beta concentration in the pancreas increases. This increase in IL-1 beta is toxic to the insulin-producing pancreatic islet cells. Death of islet cells reduces the production of insulin to control blood glucose. Eventually this destructive cycle leads to all Type 2 diabetic patients requiring insulin therapy to compensate for their inability to produce insulin. It is hypothesized that blocking IL-1 beta may improve insulin production by breaking this cycle and preserving pancreatic islet cells.

About XOMA 052

XOMA 052 is a potent anti-inflammatory monoclonal antibody targeting IL-1 beta and is being developed as a modulator of cytokine imbalance in IL-1 mediated disease states. It is an IgG2 isotype, which reduces the possibility of antibody dependent cellular cytotoxicity. With its high binding affinity of 300 fM and expected long circulating half-life, XOMA 052 may offer many patient advantages. XOMA 052 was developed by XOMA from its extensive antibody discovery infrastructure, was humanized using XOMA's Human Engineering technology, and is fully owned by XOMA. XOMA plans additional clinical trials in Type 2 diabetes and is evaluating plans to expand the development of XOMA 052 into other inflammatory diseases including rheumatoid arthritis, systemic juvenile idiopathic arthritis, and osteoarthritis.

About Type 2 Diabetes

Type 2 Diabetes is a condition characterized by high blood glucose levels caused by either a lack of insulin or the body's inability to use insulin efficiently. Type 2 diabetes develops most often in middle-aged and older adults but can appear in young people. The Centers for Disease Control and Prevention estimate that approximately 20.8 million people in the U.S. had diabetes in 2005. Type 2 diabetes is the most common form of the disease, accounting for approximately 90 percent to 95 percent of all diagnosed cases. Type 2 diabetes can lead to serious complications and premature death. However, Type 2 diabetes can be prevented or delayed, and people with diabetes can take steps to control the disease and lower the risk of serious complications. For more information about Type 2 diabetes, visit www.cdc.gov/diabetes.

About XOMA

XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies, with a therapeutic focus that includes cancer and immune diseases. XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Merck Serono S.A.) to treat moderate-to-severe plaque psoriasis, and LUCENTIS(r) (ranibizumab injection), a monoclonal antibody product marketed worldwide (by Genentech and Novartis AG) to treat neovascular (wet) age-related macular degeneration.

The company has built a premier antibody discovery and development platform that includes access to seven of the leading commercially available antibody phage display libraries and XOMA's proprietary Human Engineering(tm) and bacterial cell expression (BCE) technologies. More than 45 companies have signed BCE licenses. XOMA's development collaborators include Lexicon Pharmaceuticals, Inc., Novartis, Schering-Plough Research Institute and Takeda Pharmaceutical Company Limited. With a fully integrated product development infrastructure, XOMA's product development capabilities extend from preclinical sciences to product launch. For more information, please visit the company's website at www.xoma.com.

Certain statements contained herein concerning the development of XOMA 052 or that otherwise relate to future periods are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. These risks, including those related to the results of discovery research and preclinical testing; the timing or results of pending and future clinical trials (including the design and progress of clinical trials; safety and efficacy of the products being tested; action, inaction or delay by the FDA, European or other regulators or their advisory bodies; and analysis or interpretation by, or submission to, these entities or others of scientific data); uncertainties regarding the status of biotechnology patents; uncertainties as to the cost of protecting intellectual property; changes in the status of the existing collaborative and licensing relationships; the ability of collaborators, licensees and other third parties to meet their obligations; market demand for products; scale up and marketing capabilities; competition; international operations; share price volatility; XOMA's financing needs and opportunities and risks associated with XOMA's status as a Bermuda company, are described in more detail in XOMA's most recent annual report on Form 10-K and in other SEC filings. Consider such risks carefully in considering XOMA's prospects.

source:money.cnn.com

Low-cost diabetes drugs are equally safe

Here is a reason to smile for the sufferers of type 2 diabetes, a serious and debilitating disease that becomes progressively more common with age and obesity. A new U.S. report on Monday revealed that older oral agents for type 2 diabetes, such as sulfonylureas and metformin, are as safe and effective as newer ones.

This latest report from Consumer Reports Best Buy Drugs, a public information project of Consumers Union, is based on a thorough analysis of the scientific evidence on oral diabetes drugs by researchers at Johns Hopkins University.

After carefully examining data from more than 200 controlled clinical trials and cohort studies, Shari Bolen, M.D., M.P.H., and associates, of John Hopkins, found that older and cheaper oral drugs for type 2 diabetes, especially sulfonylureas and metformin (Glucophage) controlled blood glucose and other cardiovascular risk factors well.

Writing in the July 17 issue of the Annals of Internal Medicine, the researchers said the 12-year-old drug metformin that sold generically for about $100 a year appeared equally effective for lowering blood sugar levels.

However, metformin controls blood sugar levels about as well as the thiazolidinediones does, but it doesn't cause weight gain and actually decreases "bad" cholesterol levels, researchers said. ''It looks to be the safest,'' said Dr. Bolen.

Sponsored by the federal Agency for Healthcare Research and Quality, the systematic literature review also emphasized that glipizide and glimepiride, sold as Amaryl and Glucotrol, also have benefits.

''This is truly significant information for the millions of people with diabetes struggling to control their disease, but also struggling with the high cost of their medications,'' said Gail Shearer, project director of Consumer Reports Best Buy Drugs. "The evidence shows that lower-cost, older medicines work just as well for most people."

Although the analysis came as a good news for diabetics, it may further affect sales of Avandia, a blockbuster pill recently tied to heart problems.

Touted as “Best Buys” by the newly released report, the three low-cost generics, metformin, glipizide and glimepiride, range in cost from $10 to $60 a month, while brand-name Avandia costs $131 to $262 a month, depending on dose and Actos costs from $142 to $221, depending on dose.

Another new brand-name diabetes drug Januvia (sitagliptin phosphate), manufactured by the Whitehouse Station, New Jersey-based pharmaceutical company, Merck, costs around $200 a month.

Diabetes is a debilitating disease where the body is unable to produce or produces too little of the hormone, insulin, which is essential for controlling the level of sugar circulating in the blood.

The World Health Organization recognizes two main forms of diabetes: type 1 and type 2. Type-1 diabetes is an autoimmune disease that leaves the body without insulin to regulate the metabolism of sugar. This is a genetically associated category of diabetes, and is a condition in which the body attacks itself, destroying the pancreatic beta cells that the body needs to regulate blood sugar or glucose.

Type-2 diabetes is a condition, in which the islets of Langerhans that produce insulin are damaged. Poor diet and lifestyle habits could aggravate the disease, leading to kidney failure, amputation and eventually death.

Both Types are incurable chronic conditions, but have been treatable since insulin became medically available in 1921.

As per the estimates of International Diabetes Foundation, nearly 246 million people are currently living with diabetes. And, according to the Geneva-based WHO’s forecast, 6.4% of the global population and 8.4% of the people in the developed countries could suffer diabetes in the year 2030. Between 2000 and 2030, it said the incidence could rise by 39%.

source:www.themoneytimes.com

Diabetes Program to Educate and Empower the Patient

Health Net Federal Services, LLC (Health Net), the government operations division of Health Net, Inc. (NYSE:HNT), announced today its enhanced Disease Management diabetes program in partnership with the Department of Defense (DoD). The program enhancements align with Health Net’s goals to manage health care costs and continuously improve the quality of military health care services.

As part of the new program, the DoD will partner with Health Net to enroll beneficiaries with uncontrolled diabetes in the program, which is designed to develop a customized disease management regimen to help each beneficiary cope with their disease.

“Health Net Federal Services’ diabetes program approaches disease management through education, empowering patients to take control and participate in their health care, and learning how to effectively communicate with their doctors,” said Steve Tough, president, Health Net Federal Services.

“We believe this team offers a unique approach to controlling diabetes. All members of the team are disease specialists, including certified diabetes educators, dieticians, registered nurses and social workers. The social workers add a critical component, as it is common for patients with unmanaged chronic conditions to develop depression,” added Dr. Ted Christy, Health Net Federal Services’ vice president and acting chief medical officer. He went on to say that Health Net’s program specifically helps patients learn how to monitor, regulate and control their disease through at-home testing, regular screenings, medication, diet and exercise, and effective communication with medical professionals. Unmanaged diabetes can result in loss of vision, limbs and even life.

About Health Net

Health Net Federal Services, a subsidiary of Health Net, Inc., has a long history of providing cost-effective, quality managed health care programs for government agencies including the Department of Defense and Veterans Affairs. As the managed care support contractor for the TRICARE North Region, Health Net provides health care services to over 3 million uniformed services beneficiaries, active and retired, and their families.

Health Net, Inc. is among the nation’s largest publicly traded managed health care companies. Its mission is to help people be healthy, secure and comfortable. The company’s health plans and government contracts subsidiaries provide health benefits to approximately 6.6 million individuals across the country through group, individual, Medicare, Medicaid and TRICARE and Veterans Affairs programs. Health Net’s behavioral health subsidiary, MHN, provides mental health benefits to approximately 7.1 million individuals in all 50 states. The company’s subsidiaries also offer managed health care products related to prescription drugs, and offer managed health care product coordination for multi-region employers and administrative services for medical groups and self-funded benefits programs.

source:home.businesswire.com

The Good And The Bad About The Ubiquitous Stimulant (Caffeine)

A triple nonfat mocha may taste good, but it's likely the jolt that drives millions of people to fork over three bucks or more for the steaming cup of brown liquid.

Between 80 percent and 90 percent of North Americans consume caffeine regularly, according to a 2004 review, with an average daily consumption equivalent to about two mugs of coffee or four 16-ounce bottles of soda.

The habit has become less guilt-inducing recently, with growing evidence that both coffee and tea can fight cancer, heart disease, diabetes, Parkinson's disease and more. Because most people equate these beverages with the caffeine in them, it's tempting to conclude that the stimulant is what gives these wonder drinks their powers. That may not be the case.
Caffeine's effects on health appear to be considerably more nuanced.On the plus side, the drug does appear to help protect the brain from degenerative disease, give triathletes a nose over the finish line and, for many, keep the brain's gears churning, which is what drives most people to drink it in the first place. But habitual and large doses of caffeine can also stress the heart and interfere with insulin's ability to process sugar.

And many of the benefits ascribed to caffeine may be due, in fact, to other chemicals that outweigh caffeine's negative effects.

"As soon as you say coffee, people think caffeine; as soon as you say caffeine, people think coffee," says Terry Graham, a metabolic physiologist at the University of Guelph in Canada, a longtime caffeine researcher who recently organized an international symposium on caffeine and health.

Scientists have isolated antioxidants, polyphenols, and micronutrients from coffee and tea, but there have been no long-term studies of how each ingredient, including caffeine, affects the body on its own or within a beverage.

"There are health benefits of coffee that have nothing to do with caffeine," Graham says. In fact, he adds: "There are no health benefits I've ever seen documented for caffeine."

Anyone who has used a latte to get through an after-lunch meeting - or ended up with stomach-churning jitters after one too many shots of espresso - knows that ingesting caffeine has physical consequences. The molecule, which is identical in every beverage that contains it, blocks the action of a naturally produced chemical called adenosine.

Produced in the brain, adenosine normally accumulates during activity and declines during sleep. By the end of the day, it dulls the nervous system, causing drowsiness and a sense of calm and helping the body fall asleep. When caffeine gets in its way, by binding to adenosine receptors throughout the body, a rush of energy creates a feeling of alertness.

In dozens of studies, says Peter Rogers, lead researcher of the Dietary Caffeine and Health Study at the University of Bristol in Britain, caffeinated people have faster response times than noncaffeinated people. And a 2005 brain-imaging study showed caffeine lighting up the brain's short-term memory center.

The studies may simply prove how addictive the drug is, Rogers says. These experiments usually involve regular caffeine-drinkers who abstain for a day or two before the study.

"What we find is that if you take caffeine away from caffeine drinkers, they perform worse ... than people who don't normally get caffeine," Rogers says.

When people normally caffeine-free get caffeine, however, studies show a small to negligible mental boost, says Rogers.

It may be withdrawal that makes people falter, he says, not caffeine that makes them sharper.

A number of long-term studies comparing the overall health of heavy coffee drinkers with abstainers have turned up perplexing results, at odds with the findings of controlled experiments.

Some data, for example, suggest that drinking coffee might help prevent heart disease. Coffee contains thousands of compounds that might be responsible for such benefits, but polyphenols, similar to the healthful compounds found in chocolate and red wine, as well as antioxidants are the most likely candidates.

Several large studies have linked large daily doses of coffee with lower rates of Parkinson's disease, as well. And coffee drinking has also been linked to lower rates of liver cancer, Type 2 diabetes and gout, among other ills.

Scientists warn that the benefits probably come from ingredients other than caffeine.

Pure caffeine, in fact, can exacerbate the symptoms of diabetes. Graham and colleagues have done studies that showed caffeine makes insulin less efficient at removing sugar from the bloodstream.

In serious athletes, though, caffeine can enhance both speed and endurance by helping muscles contract with slightly more force. Caffeine in the form of sports drinks, soda or pills can improve endurance, he says, but coffee doesn't work. "Our only conclusion is that there must be factors in coffee that work in the opposite fashion," Graham says.

source:www.courant.com

Dairy Products Reduce Risk of Diabetes & Heart Disease

A 20-year study has found that men who get enough dairy are at a substantially lower risk for diabetes and heart disease. The data shows that drinking at least 16 ounces of milk a day makes men 62% less likely to develop health conditions such as high blood fats and high blood pressure. Doctors caution that people shouldn't consume large amounts of dairy products and should instead incorporate it as part of a balanced diet.

source:www.wlns.com

New genetic clue to Type 1 diabetes

A faulty gene on Chromosome 16 boosts the risk of developing Type 1 diabetes, according to the latest probe into the causes of this disease.

Three variants of a gene called KIAA0350 were spotted as risk factors in a genetic profiling of 563 patients with Type 1 diabetes, which were compared to 1 146 healthy people, says the study, published online on Sunday by Nature.

Type 1 diabetes occurs when the immune system destroys cells in the pancreas that produce insulin, the hormone that regulates blood glucose.

It is also called "juvenile" or "childhood" diabetes, because it often emerges in a patient's early years.
The research led by Hakon Hakonarson, of the Children's Hospital of Philadelphia, Pennsylvania, adds to the list of suspected genes, spotted on Chromosomes 6, 11, 1 and 2, each of which appear to play different roles in the disease.

Diabetes is a chronic condition in which the body does not produce enough of the hormone insulin, or cannot make proper use of the insulin it does produce, a condition called insulin resistance.

As a result, there are wild fluctuations of glucose in the blood. This can eventually lead to blindness, heart disease, amputations and kidney failure.

Type 1 diabetes is linked to genetic predisposition. The far more common Type 2 diabetes results mainly from an unhealthy diet and inactivity and is becoming epidemic in scale in many developed or fast-developing countries.

Predicting genetic vulnerability to diabetes could offer huge benefits, doctors believe.

In most cases of Type 1 diabetes, many patients are diagnosed too late to save the so-called beta cells that produce the insulin.

source:www.iol.co.za

Labels